Anthera Pharmaceuticals, Inc. (ANTH)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 30, 2025, 8:00 PM EDT
Market Cap2.62K
Revenue (ttm)n/a
Net Income (ttm)-24.93M
Shares Out26.18M
EPS (ttm)-1.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,790
Average Volume61
Open0.0001
Previous Close0.0001
Day's Range0.0001 - 0.0001
52-Week Rangen/a
Beta-99.27
RSI53.92
Earnings Daten/a

About Accolade

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 21
Stock Exchange OTCMKTS
Ticker Symbol ANTH
Full Company Profile

Financial Performance

Financial Statements

News

AM Best Assigns Issue Credit Ratings to Anthem, Inc.'s New Senior Unsecured Notes

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned Long Term Issue Credit Ratings of “bbb+” to the newly issued senior unsecured notes of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE:ANTH], which ...

4 years ago - Business Wire

AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Announcement

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has commented that the Credit Ratings (ratings) of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE: ANTH] and its insurance subsidiaries remain unchanged followi...

4 years ago - Business Wire